Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study to evaluate how GLP-1 therapy combined with KYZATREX impacts muscle mass and energy levels in male patients undergoing weight loss

Next Previous
Trial Profile

A clinical study to evaluate how GLP-1 therapy combined with KYZATREX impacts muscle mass and energy levels in male patients undergoing weight loss

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Testosterone undecanoate (Primary) ; Glucagon-like peptide-1 receptor agonists
  • Indications Muscle weakness; Weight loss
  • Focus Therapeutic Use

Most Recent Events

  • 03 Oct 2024 New trial record
  • 25 Sep 2024 According to a NUBIOAGE LLC media release, Bryan Gard, PA-C, head of Gard Wellness Solutions, will oversee patient care as the lead specialist in Hormone Replacement Therapy (HRT) and weight loss.
  • 25 Sep 2024 According to a NUBIOAGE LLC media release, Marius Pharmaceuticals will supply KYZATREX for this study in partnership with nuBioAge, who is responsible for assembling the study and data interpretation alongside nuHx, who will be performing the ongoing assessments for the patients participating in the study. Patients will be recruited and supplied with medication through Progress Pharmacy, with study design and data analytics supported by Palm Beach Atlantic University's School of Pharmacy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top